Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Santhera Pharmaceuticals Holding AG    SANN   CH0027148649

SANTHERA PHARMACEUTICALS HOLDING AG

(SANN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Santhera Completes Capital Increase for Financing Arrangements

11/25/2020 | 01:00am EST


Pratteln, Switzerland, November 25, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 937,928 treasury shares. The number of shares recorded in the commercial register has been increased to 18,983,321 shares.

On November 24, 2020, 937,928 shares were issued out of the existing authorized capital as treasury shares. Santhera expects to use these shares for purposes of its financing arrangements. The new shares will be listed as per November 25, 2020.

About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera has an exclusive license for all indications worldwide to vamorolone, a first-in-class dissociative steroid with novel mode of action, currently investigated in a pivotal study in patients with DMD as an alternative to standard corticosteroids. The clinical stage pipeline also includes lonodelestat (POL6014) to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases, as well as an exploratory gene therapy approach targeting congenital muscular dystrophies. Santhera out-licensed ex-North American rights to its first approved product, Raxone® (idebenone), for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group. For further information, please visit www.santhera.com

Raxone® is a trademark of Santhera Pharmaceuticals.

For further information please contact:
public-relations@santhera.com or
Eva Kalias, Head External Communications
Phone: +41 79 875 27 80
eva.kalias@santhera.com

Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

# # #

Attachment


Primary Logo


© GlobeNewswire 2020
All news about SANTHERA PHARMACEUTICALS HOLDING AG
2020SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
AQ
2020Santhera Pharmaceuticals Closes Issuance of Treasury Shares
MT
2020SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
PU
2020SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
AQ
2020PRESS RELEASE : Santhera Completes Capital Increase for Financing Arrangements
DJ
2020SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
AQ
2020SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
DJ
2020Santhera Completes Capital Increase for Financing Arrangements
GL
2020Santhera Pharmaceuticals Partner ReveraGen Gets $3 Million Funding to Advance..
MT
2020SANTHERA PHARMACEUTICALS : ReveraGen Receives $3.3 Million NIH Commercialization..
PU
More news
Financials
Sales 2020 14,6 M 16,5 M 16,5 M
Net income 2020 -55,3 M -62,3 M -62,3 M
Net Debt 2020 - - -
P/E ratio 2020 -0,90x
Yield 2020 -
Capitalization 57,9 M 65,0 M 65,2 M
Capi. / Sales 2020 3,96x
EV / Sales 2021 2,08x
Nbr of Employees 113
Free-Float 85,3%
Chart SANTHERA PHARMACEUTICALS HOLDING AG
Duration : Period :
Santhera Pharmaceuticals Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANTHERA PHARMACEUTICALS HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 5,35 CHF
Last Close Price 2,85 CHF
Spread / Highest target 170%
Spread / Average Target 87,7%
Spread / Lowest Target 5,26%
EPS Revisions
Managers and Directors
NameTitle
Dario Eklund Chief Executive Officer
Elmar J. Schnee Chairman
Andrew P. Smith Chief Financial Officer
Thomas Meier Director
Martin Gertsch Vice Chairman
Sector and Competitors